Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBI 4000

Next Previous
Drug Profile

RBI 4000

Alternative Names: RBI-4000

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomic Therapeutics; Replicate Bioscience
  • Developer Replicate Bioscience
  • Class Antineoplastics; Immunotherapies; RNA; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rabies
  • Preclinical Infections
  • No development reported Prostate cancer

Most Recent Events

  • 04 Dec 2025 Replicate Bioscience and Instituto Butantan enter into collaborative agreement to develop and commercialise RBI 4000 in Brazil and other Latin American countries
  • 04 Dec 2025 Instituto Butantan plans to conduct registrational clinical trials of RBI 4000 for Rabies (Prevention)
  • 24 Sep 2025 Adverse events and Immunoglobulin data from a phase I trial in Rabies released by Replicate Bioscience

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top